1. Introduction {#sec1-jcm-08-00592}
===============

Chronic kidney disease (CKD) is associated with a higher risk for cardiovascular events (CVE) \[[@B1-jcm-08-00592]\]. This increased risk seems to be strongly associated with electrolyte disturbances in dialysis patients, with a higher burden of atheromatous plaque playing a paramount role in the earlier stages \[[@B2-jcm-08-00592],[@B3-jcm-08-00592]\]. In agreement with this hypothesis, atherosclerosis associated biomarkers showed good prognostic capacity to predict CVE in CKD patients \[[@B4-jcm-08-00592]\], and the combination of some biomarkers associated with the presence of atheromatous plaque like Osteoprotegerin (OPG), Osteopontin (OPN) and soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) increased the accuracy of predictive models for cardiovascular outcomes in CKD patients \[[@B5-jcm-08-00592]\].

OPN is an extracellular matrix glycoprotein produced by cells involved in bone morphogenesis, which plays a major role in the control of biomineralization and calcification. OPN is a secreted protein that contains several functional domains, including a number of integrin-interacting domains which facilitate the recruitment of inflammatory cells \[[@B6-jcm-08-00592]\]. It is upregulated in atherosclerotic settings, where it is expressed by macrophages, endothelial and vascular smooth muscle cells, and modulates the inflammatory response by recruiting multiple inflammatory cell types \[[@B7-jcm-08-00592],[@B8-jcm-08-00592],[@B9-jcm-08-00592]\]. Mice overexpressing OPN show smooth muscle cell hyperproliferation, medial thickening, and neointimal formation \[[@B10-jcm-08-00592]\], and mice with OPN deficiency display attenuated atherosclerosis \[[@B11-jcm-08-00592]\]. In clinical studies, increased plasma OPN expression levels are associated with the presence and severity of coronary artery disease \[[@B12-jcm-08-00592],[@B13-jcm-08-00592]\] and with the levels of calcification \[[@B12-jcm-08-00592],[@B14-jcm-08-00592]\]. Furthermore, the levels of OPN are also affecting the degree of neointima formation and of restenosis after revascularization, both in humans and in animal studies \[[@B10-jcm-08-00592],[@B15-jcm-08-00592],[@B16-jcm-08-00592]\]. Finally, several studies have related high circulating levels of OPN to adverse cardiovascular events in the general population \[[@B17-jcm-08-00592]\] and in CKD patients \[[@B18-jcm-08-00592]\].

Apart from plasma OPN levels, single nucleotide polymorphisms (SNPs) on the *SPP1* gene (the gene encoding OPN), have also been associated with atheromatous disease and cardiovascular events \[[@B19-jcm-08-00592]\]. For instance, rs28357094 located at the *SPP1* promoter has been shown to be related with increased carotid intima media thickness (cIMT) \[[@B20-jcm-08-00592],[@B21-jcm-08-00592]\]. A second SNP, rs11730582 has also been associated with increased cIMT in stroke patients \[[@B21-jcm-08-00592]\]. However, these results are questioned, as some researchers found no association between these polymorphisms and atherosclerotic markers \[[@B22-jcm-08-00592],[@B23-jcm-08-00592]\]. Furthermore, most of the studies focusing in *SPP1* SNPs do not quantify plasma OPN, precluding further analysis on its effects on OPN levels.

In view of these data, we studied the association of SNPs in the *SPP1* gene and circulating levels of OPN with the incidence of CVE in a cohort of CKD patients during a 48 month period.

2. Experimental Section {#sec2-jcm-08-00592}
=======================

2.1. Study Design and Participants {#sec2dot1-jcm-08-00592}
----------------------------------

The NEFRONA (Observatory of Atherosclerosis in Nephrology) project is an observational, multi-center, prospective study that, from 2010 to 2012, recruited 2445 CKD patients from all over Spain \[[@B24-jcm-08-00592],[@B25-jcm-08-00592]\]. Inclusion criteria were to present CKD stage 3 or higher (including patients in dialysis) and absence of any previous cardiovascular disease; CKD stage 3 was defined as glomerular filtration rate \< 60 mL/min/1.73 m^2^ according to the 4-variable Modification of Diet in Renal Disease (MDRD) equation \[[@B26-jcm-08-00592],[@B27-jcm-08-00592]\]. Exclusion criteria were life expectancy below 1 year, previous carotid surgery, acquired immune deficiency syndrome infection, having any organ transplant, any infection or hospital admission during the month previous to be included and pregnancy. We also included 559 controls (MDRD above 60 mL/min/1.73 m^2^) matched by age and sex randomly recruited from several Spanish Primary Care centers during the same period (2010 to 2012).

On the inclusion day, we obtained anthropometric, demographic, and biochemical data together with a comprehensive vascular ultrasound analysis to assess the presence of atherosclerotic plaque \[[@B28-jcm-08-00592]\].

Volunteers underwent a minimum of 4 years of follow-up and CVE events (fatal and non-fatal) were recorded by the referring physician. CVE included unstable angina, myocardial infarction, transient ischemic attack, cerebrovascular accident, congestive heart failure, arrhythmia, peripheral artery disease, amputation due to vascular disease, aortic aneurysm, myocardial infarction, arrhythmia, congestive heart failure, stroke, mesenteric infarction, and sudden death. All patients were clearly informed, and signed an informed consent; the local Ethics Committee of each hospital approved the protocol.

2.2. SNP Genotyping {#sec2dot2-jcm-08-00592}
-------------------

DNA was obtained from blood samples stored at the Biobank of the Spanish Renal Research Network (REDinREN) \[[@B29-jcm-08-00592]\] using the QIAamp DNA Blood Kit and following manufacturer instructions. Genotyping was performed with matrix assisted laser desorption ionization time-of-flight mass spectrometry in the Sequenom MassARRAY platform^®^, in Centro de Genotipado-Plataforma de Recursos Biomoleculares y Bioinformáticos (CEGEN-PRB2) del Instituto de Salud Carlos III (Nodo de la Universidad de Santiago de Compostela, A Coruña, Spain). As a quality control, we eliminated SNP clusters or samples with low genotyping percentage and SNPs not meeting the Hardy--Weinberg Equilibrium (HWE). We included replicates of samples between plates and samples from the Coriell Institute Biorepository for genotyping quality assessment. For this study, we focused on five SNPs distributed along the *SPP1* gene in the 5′ upstream region (rs11730582 and rs28357094), the coding region (rs1126616) and the 3′ untranslated region (rs9138 and rs1126772).

2.3. Determination of OPN Levels {#sec2dot3-jcm-08-00592}
--------------------------------

OPN serum levels were measured using MILLIPLEX^®^ MAP kits (EMD Millipore Corporation, Darmstadt, Germany) in a blinded manner. Minimum detectable levels were 37.7 pg/mL, intra-assay coefficient of variation 2%, and inter-assay coefficient of variation 12%.

2.4. Statistical Analysis {#sec2dot4-jcm-08-00592}
-------------------------

Qualitative variables were expressed as *n* (%), and quantitative variables as median (Q1;Q3) or mean (SD) depending on normality of distribution. Comparisons between groups were performed with Mann--Whitney U test or Student's *t* test for non-normally or normally distributed quantitative variables, respectively, and Chi-squared test for categorical data.

To determine the genotypic association, genotype frequency, single SNP frequency under multiple inheritance models, haplotype frequency, and haplotype association with the response we used SNPStats \[[@B30-jcm-08-00592]\]. Linkage disequilibrium (LD) was calculated with HAPLOVIEW \[[@B31-jcm-08-00592]\] and compared to IBS population (Iberian Population in Spain) from Ensembl \[[@B32-jcm-08-00592]\].

Kaplan--Meier curves were used to assess time to outcome according to a multiple markers score, and compared with the Mantel--Cox test. Time to event analysis was done using the Cox proportional hazards model, including adjustment for potential confounding factors. Final model was obtained through a forward stepwise method based on the likelihood ratio test. Data were presented as hazard ratios (HRs) and 95% confidence intervals (95% CIs), and *p* value \< 0.05 was considered statistically significant.

3. Results {#sec3-jcm-08-00592}
==========

In the median follow-up period of 48.1 months, 206 CVE were reported (7.3%). The group of patients suffering a CVE were older, predominantly males, with a higher body mass index, systolic blood pressure and urine albumin to creatinine ratio, and showed an increased proportion of other classical cardiovascular risk factors (smoking, diabetes, hypertension, and dyslipemia). The group of patients suffering a CVE also displayed a higher percentage of patients in a more advanced CKD stage and with atheromatous plaque. Furthermore, they had lower levels of total, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol and higher triglycerides. In addition, blood levels of phosphorus, potassium, and ultra-sensitive c-reactive protein usCRP were higher whereas levels of 25(OH) vitamin D were lower. Levels of OPN were also significantly higher in the group of patients suffering a CVE ([Table 1](#jcm-08-00592-t001){ref-type="table"}).

All the SNPs followed the HWE ([Supplemental Table S1](#app1-jcm-08-00592){ref-type="app"}). We analyzed the crude association of the five SNPs (rs9138, rs1126616, rs1126772, rs11730582 and rs28357094) with CVE by testing five different models: co-dominant, dominant, recessive, over dominant and log-additive. [Table 2](#jcm-08-00592-t002){ref-type="table"} shows the three SNPs that were significantly associated with higher odds of having a CVE under the selected genetic model. Complete information for all SNPs and models is shown in [Supplemental Tables S2--S6](#app1-jcm-08-00592){ref-type="app"}. For rs1126616 and rs9138, the over dominant models yielded significant differences, and for rs1126772 the dominant model returned the highest odds ratio and the lowest *p* value. As the three SNPs are in almost complete linkage disequilibrium ([Figure 1](#jcm-08-00592-f001){ref-type="fig"}), for further analysis we only considered the rs1126616, as the number of missing values was lower in this SNP.

Taking into account the importance of rs1126616, we performed a Kaplan--Meier survival analysis to determine its effect on CVE. [Figure 2](#jcm-08-00592-f002){ref-type="fig"} shows that patients with homozygote genotypes present a lower incidence of CVE than patients with the heterozygote genotype. The differences between both groups were assessed with a log-rank test, reaching a significant *p* value of 0.029.

When our cohort was analyzed according to the proposed genetic model, significant differences were observed only for the incidence of CVE ([Table 3](#jcm-08-00592-t003){ref-type="table"}). Notably, OPN levels were almost equal between both groups and were similarly modified by the CKD stage ([Figure 3](#jcm-08-00592-f003){ref-type="fig"}).

Then we performed a multivariate proportional hazards Cox regression analysis including clinical and biochemical variables theoretically associated with a higher risk of presenting a CVE, together with the rs1126616 polymorphism. As shown in [Table 4](#jcm-08-00592-t004){ref-type="table"}, variables with a statistically significant association with CVE were older age, the presence of diabetes and atheromatous plaque, higher levels of phosphate and c-reactive protein, and lower levels of HDL cholesterol and vitamin D. Heterozygosity for the rs1126772 genotype was associated with higher hazards of having a CVE.

Although the previous model was adjusted by CKD stage, we performed a sensitivity analysis eliminating the dialysis patients because they have a higher mortality rate. Thus, in [Table 5](#jcm-08-00592-t005){ref-type="table"} we show the Cox regression model further adjusted by proteinuria. The results show that the rs1126616 polymorphism is still significantly associated with the incidence of CVE.

4. Discussion {#sec4-jcm-08-00592}
=============

Cardiovascular events are one of the main complications of CKD patients, in which cardiovascular mortality is the main cause of death \[[@B33-jcm-08-00592]\]. The causes of this excess of cardiovascular complications are not clear, although an increase in atherosclerotic-related problems has been suggested \[[@B3-jcm-08-00592],[@B34-jcm-08-00592]\]. Accelerated atherosclerosis is a clinical feature associated with CKD \[[@B35-jcm-08-00592]\], but the mechanisms involved are not fully understood. Among the metabolic alterations presented by CKD patients that could be involved in the excessive cardiovascular complications, changes in mineral metabolism are suggested to play a role \[[@B2-jcm-08-00592],[@B36-jcm-08-00592],[@B37-jcm-08-00592]\]. OPN is a protein that is implicated in calcification, proliferation, and migration of vascular smooth muscle cells, providing a possible link between mineral metabolism and formation of atheroma plaque \[[@B38-jcm-08-00592],[@B39-jcm-08-00592],[@B40-jcm-08-00592]\].

There is a clear association of OPN protein levels with atherosclerosis \[[@B6-jcm-08-00592]\] and cardiovascular disease \[[@B41-jcm-08-00592]\], and many studies have shown an association of higher OPN levels with CVE in several populations, including the NEFRONA cohort \[[@B5-jcm-08-00592],[@B42-jcm-08-00592],[@B43-jcm-08-00592],[@B44-jcm-08-00592]\]. In our analysis, in agreement with previous reports, OPN levels increased progressively with the degree of renal function impairment \[[@B18-jcm-08-00592]\], and were higher in patients with CVE. However, after adjustment for traditional risk factors and rs1126616, OPN levels were no longer significantly associated with the incidence of CVE. In any case, in the multivariate proportional hazards Cox regression analysis, the higher tertile of OPN almost reached statistical significance (Hazard Ratio: 2.9; *p* = 0.088; data not shown) so probably, the relatively low number of events precluded the analysis from having enough potency to show the association of OPN levels with CVE.

Currently, there are few studies analyzing OPN polymorphisms and CVE. The results of the present study demonstrate that rs1126616 polymorphism of the *SPP1* gene is independently associated with a higher incidence of CVE in a cohort of CKD patients. A previous study from Brand-Herrmann and colleagues did not find any association of the *SPP1* rs1126616 SNP to myocardial or brain infarction \[[@B19-jcm-08-00592]\], but differs from our study in many aspects. The NEFRONA study is a prospective cohort study of mainly CKD patients, and our endpoint (CVE) is a composite containing all cardiovascular events. Norman et al. investigated the association between OPN SNPs and abdominal aortic aneurysm (AAA), and found no significant associations between rs1126616 and AAA or aortic diameter, neither with aortic expansion nor with OPN levels \[[@B45-jcm-08-00592]\]. Again, the fact that their cohort was not composed of CKD patients, and that they only focus on AAA could explain differences between both studies. It is worth noting that none of these studies \[[@B19-jcm-08-00592],[@B45-jcm-08-00592]\] tested different genetic models of inheritance, precluding the identification of the over dominant genotype that arose in our study. Usually genetic disease models follow dominant, recessive, or co-dominant models, but over dominant models have been also described in many studies \[[@B46-jcm-08-00592],[@B47-jcm-08-00592],[@B48-jcm-08-00592],[@B49-jcm-08-00592]\].

Apart from CVE, the rs1126616 polymorphism has also been found to be associated with CKD \[[@B50-jcm-08-00592]\], urolithiasis \[[@B51-jcm-08-00592]\], and to the prevalence of lupus nephritis \[[@B52-jcm-08-00592]\]. However, no study has previously shown the effect of the SNP on circulating levels of OPN in patients with different stages of CKD. Previous reports have shown no differences in OPN levels between different genotypes of the SNP \[[@B51-jcm-08-00592],[@B52-jcm-08-00592],[@B53-jcm-08-00592]\]. Our results agree with the previous literature as the different genotypes do not modify the OPN levels, and more advanced stages of CKD show increased levels of OPN. The rs1126616 is not expected to change either the expression of the gene or the sequence of the protein as the SNP is a synonymous change (p.Ala236=) located at the coding region. In our population, rs1126616 is in almost complete LD with the other two SNPs that, consequently, yielded statistically significant differences in the univariate analysis (rs1126772 and rs9138). These two SNPs are located at the 3′ untranslated region but in our study, and in agreement with previous reports \[[@B51-jcm-08-00592],[@B52-jcm-08-00592],[@B53-jcm-08-00592]\], the OPN levels did not change according to these genotypes. Therefore, we cannot rule out that the association found between this SNP and the presence of CVE could be due to another functional SNP in LD with the one we studied.

One limitation of our work is the lack of a validation cohort. As a second limitation, previous Genome-Wide Association Studies (GWAS) did not find any association between any of the present polymorphisms and cardiovascular disease \[[@B54-jcm-08-00592]\]. However, this could be due to the very strict limitations applied to *p* values in those kind of studies. As for strengths of the current work, this is the first time that *SPP1* gene polymorphisms have been analyzed in a relatively large CKD population on which OPN levels have been related to phenotype and genotype. Moreover, the many clinical and biochemical data of NEFRONA study allowed us to better adjust and to put into context the effect of the selected SNPs.

In conclusion, the rs1126616 SNP of the *SPP1* gene is independently associated with cardiovascular events in a cohort of CKD patients regardless of OPN levels and thus, if validated, could be used to predict CVE risk in CKD patients.
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jcm-08-00592-t001_Table 1

###### 

Epidemiological, clinical, and biochemical parameters of patients according to the presence or absence of cardiovascular events.

  Variable                          No CVE            CVE                 *p* Value   
  --------------------------------- ----------------- ------------------- ----------- ---------
  Age (years)                       59 (48;67)        64.5 (58;70)        \<0.001     
  Sex (Female)                      1056 (40.4)       60 (29)             0.001       
  Body mass index (kg/m^2^)         27.6 (24.6;31)    28.9 (25.7;32.12)   0.005       
  Smoking (Yes)                     1481 (56.7)       137 (66.5)          0.006       
  Diabetes (Yes)                    546 (20.9)        88 (42.7)           \<0.001     
  Hypertension (Yes)                2068 (79.2)       191 (92.7)          \<0.001     
  Dyslipemia (Yes)                  1551 (59.4)       149 (72.3)          \<0.001     
  Systolic blood pressure (mmHg)    140 (21.3)        148 (24.7)          \<0.001     
  Dyastolic blood pressure (mmHg)   81 (11)           81 (13)             0.556       
  Chronic kidney disease Stage      Control           536 (20.5)          13 (6.3)    \<0.001
  Stage 3                           819 (31.4)        66 (32)                         
  Stage 4--5                        684 (26.2)        62 (30.1)                       
  Dialysis                          570 (21.8)        65 (31.6)                       
  Presence of plaque at baseline    1684 (64.5)       186 (90.3)          \<0.001     
  Total Cholesterol (mg/dL)         182 (156.5;208)   171 (141.2;207)     0.017       
  HDL Cholesterol (mg/dL)           48 (39;59\]       44 (35;52)          \<0.001     
  LDL Cholesterol (mg/dL)           105 (83;128)      98 (72;128)         0.042       
  Triglycerides (mg/dL)             118 (86.2;166)    138 (100;181)       \<0.001     
  Glucose (mg/dL)                   96 (87;110)       105 (91.6;139.2)    \<0.001     
  Calcium (mg/dL)                   9.3 (8.8;9.5)     9.3 (8.9;9.7)       0.095       
  Phosphate (mg/dL)                 3.8 (3.3;4.4)     4 (3.4;5)           0.003       
  Sodium (mEq/L)                    140.6 (139;142)   140 (138;142)       0.015       
  Potassium (mEq/L)                 4.7 (4.37;5.1)    4.9 (4.4;5.3)       \<0.001     
  C-reactive protein (mg/L)         4.2 (8.2)         6.2 (12)            0.001       
  ACR (mgAlb/gCreat)                ACR \< 30         398 (34.3)          20 (22.2)   0.02
  ACR = 30--300                     416 (35.9)        32 (35.6)                       
  ACR \> 300                        346 (29.8)        38 (42.2)                       
  25(OH) vitamin D (ng/mL)          17.1 (7.8)        14.6 (6.9)          \<0.001     
  OPN (ng/mL)                       16.7 (9.3;33)     22.6 (11.9;53.3)    \<0.001     

Qualitative variables are expressed as *n* (%) and quantitative variables as median (Q1;Q3) or mean (SD) depending on the normality of the distribution. Comparisons between groups performed with Mann--Whitney U test or Student's *t* test for quantitative non-normally distributed variables and normally distributed respectively, and Chi-squared test for categorical data. CVE, cardiovascular events; HDL, high-density lipoprotein; LDL, low-density lipoprotein; ACR, urine albumin to creatinine ratio; OPN, Osteopontin.

jcm-08-00592-t002_Table 2

###### 

Selected models of inheritance for the three *SPP1* polymorphisms associated with the presence of cardiovascular events.

  SNP (*n*)         Model           Genotype     NO CVE *n* (%)         CVE *n* (%)   Odds Ratio (95% CI)   *p* Value
  ----------------- --------------- ------------ ---------------------- ------------- --------------------- -----------
  rs1126616(2815)   Over dominant   CC-TT        1512 (58)              102 (49.5)    1.00                  0.019
  CT                1097 (42)       104 (50.5)   1.41 (1.06--1.87) \*                                       
  rs1126772(1613)   Dominant        AA           903 (59.9)             49 (46.2)     1.00                  0.006
  AG-GG             604 (40.1)      57 (53.8)    1.74 (1.17--2.58) \*                                       
  rs9138(2815)      Over dominant   AA-CC        1549 (59.3)            106 (51.5)    1.00                  0.028
  AC                1062 (40.7)     100 (48.5)   1.38 (1.04--1.83) \*                                       

\* Significant odds ratio. Odds ratio is referred to dominant homozygote for each model. The *p* value is for model performance for each individual polymorphism against other possible models (co-dominant, dominant, recessive, over dominant, log-additive). CVE, cardiovascular event; SNP: single nucleotide polymorphisms; 95% CIs: 95% confidence intervals; *SPP1*: Osteopontin gene.

jcm-08-00592-t003_Table 3

###### 

Association of *SPP1* rs1126616 C \> T polymorphism with epidemiological, clinical and biochemical parameters of the cohort.

  Variables                         GENOTYPES       GENOTYPE        *p* Value    
  --------------------------------- --------------- --------------- ------------ -------
  Age (years)                       56.36(12.48)    57.96(12.48)    0.219        
  Sex (Female)                      619(39.8)       457(39.1)       0.719        
  Body mass index (kg/m^2^)         28.12(5)        28.38(5.1)      0.186        
  Smoking (Yes)                     886(57)         689(59)         0.293        
  Diabetes (Yes)                    357(23)         253(21)         0.442        
  Hypertension (Yes)                1225(78.8)      953(81.6)       0.069        
  Dyslipemia                        946(60.8)       703(60.2)       0.732        
  Systolic blood pressure (mmHg)    140.99(21.47)   141.17(21.71)   0.823        
  Dyastolic blood pressure (mmHg)   81.14(11.39)    80.93(11.34)    0.627        
  Chronic kidney disease Stage      Control         334(21.5)       205(17.6)    0.058
  Stage 3                           485(31.2)       382(32.7)                    
  Stage 4--5                        413(26.6)       310(26.5)                    
  Dialysis                          323(20.8)       271(23.2)                    
  Cardiovascular Events             100(6.4)        101(8.6)        0.029        
  Any basal plaque (yes)            1048(67.4)      785(67.2)       0.918        
  Total Cholesterol (mg/dL)         183.71(40,44)   182.66(38.73)   0.5          
  HDL Cholesterol (mg/dL)           50.45(15.49)    50.12(15.41)    0.606        
  LDL Cholesterol (mg/dL)           107.32(35.21)   106.42(34.08)   0.534        
  Triglycerides (mg/dL)             136.58(76.54)   140.85(81.53)   0.17         
  C-reactive protein                4.33(8.55)      4.34(8.26)      0.964        
  ACR (mgAlb/gCreat)                ACR \< 30       239 (34.9)      168 (31.2)   0.390
  ACR = 30--300                     242 (35.3)      201 (37.3)                   
  ACR \> 300                        204 (29.8)      170 (31.5)                   
  Glucose (mg/dL)                   106.76(39.22)   105.91(34.23)   0.55         
  Calcium (mg/dL)                   9.32(0.58)      9.35(0.55)      0.18         
  Phosphate (mg/dL)                 3.97(1.06)      3.96(1.05)      0.768        
  Sodium (mEq/L)                    140.36(2.97)    140.51(2.98)    0.176        
  Potassium (mEq/L)                 4.75(0.6)       4.74(0.56)      0.642        

*p* value \< 0.05 boldface typed. Qualitative variables are expressed as n (%) and quantitative variables as mean (SD). Comparisons between groups performed with Student's *t* test for quantitative variables, and Chi-squared test for categorical data. HDL, high-density lipoprotein; LDL, low-density lipoprotein; ACR, urine albumin to creatinine ratio; OPN, Osteopontin.
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###### 

Cox regression modelling the incidence of CVE including dialysis patients (*n* = 2093).

  Variables                  HR (95% CI)            *p* Value
  -------------------------- ---------------------- -----------
  Age (years)                1.020 (1.003--1.038)   0.024
  Diabetes                   1.705(1.23--2.36)      0.001
  HDL Cholesterol (mg/dL)    0.983(0.972--0.995)    0.005
  Phosphate (mg/dL)          1.387(1.218--1.579)    \<0.001
  25(OH) vitamin D (ng/mL)   0.95(0.924--0.976)     \<0.001
  C-reactive protein         1.013(1.001--1.024)    0.037
  Plaque presence            2.555(1.461--4.468)    0.001
  rs1126616                  1.462(1.067--2.004)    0.018

Variables that did not reach significance level: Sex, BMI, Smoker, Hypertension, Dyslipemia, Systolic blood pressure (SBP), Diastolic blood pressure (DBP), CKD stage, Total cholesterol, LDL cholesterol, triglycerides, glucose, calcium, and OPN tertile. HR, Hazard Ratio. CI: Confidence Intervals.
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###### 

Cox regression modelling the incidence of CVE excluding dialysis patients (*n* = 1021).

  Variables                 HR (95% CI)           *p* Value
  ------------------------- --------------------- -----------
  Diabetes                  1.913(1.196--3.060)   0.007
  HDL Cholesterol (mg/dL)   0.975(0.957--0.994)   0.008
  Plaque presence           2.438(1.265--4.697)   0.008
  C-reactive protein        1.019(1.005--1.034)   0.01
  rs1126616                 1.626(1.026--2.576)   0.039

Variables that did not reach significance level: Age, Sex, BMI, Smoker, Hypertension, Dyslipemia, SBP, DBP, CKD stage, Total cholesterol, LDL cholesterol, triglycerides, albumin to creatinine ratio, glucose, calcium, phosphate, 25(OH) vitamin D and OPN tertile. HR: Hazard Ratio; CI: Confidence Intervals.

[^1]: These authors on behalf of the NEFRONA investigators.
